More on the Tax-Cuts-and-Medicaid-Cuts Bill, Including an Apex Analysis of a Biotech-Boosting R&D Tax Provision
Shares:
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
I was working through the full newsletter this morning when I saw that the Minnesota 340B report dropped. So I think it’s worth a special edition today. That doesn’t mean
There is so much going on in the drug-pricing world that the media can’t always track it all down, so -- as much as I respect all the journalism out